{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-001666","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.780101+00:00","generated_at":"2026-06-20T07:14:41.404655+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia receives key patent allowance for LUPKYNIS dosing and PTAB terminates IPR challenge","bullets":["USPTO allowed patent application 17/713,140 for LUPKYNIS dosing with eGFR, extending protection to 2037.","PTAB terminated Inter Partes Review of Aurinia's U.S. Patent No. 10,286,036 (Orange Book-listed).","New patent supplements existing method-of-use patent; Aurinia intends to list it in Orange Book when issued."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-001666","json":"https://secwatch.observer/filing/0001628280-23-001666.json","markdown":"https://secwatch.observer/filing/0001628280-23-001666.md","text":"https://secwatch.observer/filing/0001628280-23-001666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023001666/0001628280-23-001666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828023001666/auph-20230124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:14:41.404655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}